The Evolution of Commercial Antibody Formulations

化学 抗体 生物 免疫学
作者
Carl Mieczkowski
出处
期刊:Journal of Pharmaceutical Sciences [Elsevier BV]
卷期号:112 (7): 1801-1810 被引量:13
标识
DOI:10.1016/j.xphs.2023.03.026
摘要

It has been nearly four decades since the first therapeutic monoclonal antibodies were approved and made available for widespread human use. Herein, US and EU approved antibody formulations are reviewed, and their nature and compositions are evaluated over time. From 1986 through Jan 2023, significant formulation trends have occurred and to represent this, 165 commercial antibody therapeutic formulations were binned into 5 different periods of time. Overall, we have observed the following: 1) The average formulation pH has decreased in recent years by over 0.5 units along with a decrease in variability that is largely driven by non-high concentration liquid in vial presentations for IV administration, 2) The use of certain excipients and buffers such as histidine, sucrose, metal chelators, arginine and methionine has become significantly more common, whereas formulations that contain phosphate, salt, no sugar or no surfactant have fallen out of favor, 3) Overall formulation space has increasingly become more homogenous and has converged in terms of formulation pH and excipient preferences regardless of formulation concentration, drug product presentation, and route of administration, 4) The average calculated isoelectric point (pI) has decreased 0.26 units, and 5) Overall, the average formulation pH and calculated pI for all commercial antibodies surveyed was 6.0 and 8.4, respectively. These trends and formulation convergence may be driven by multiple factors such as advancements in high-throughput computational and analytical technologies, the increased emphasis and understanding of certain developability attributes and formulation principles during lead selection and formulation development, and the adoption of low-risk development platform approaches.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
七七完成签到 ,获得积分10
刚刚
刚刚
chenli900108发布了新的文献求助10
刚刚
科研通AI5应助斯文明杰采纳,获得10
1秒前
1秒前
小蚊子发布了新的文献求助10
1秒前
YZZ发布了新的文献求助10
1秒前
大个应助kk采纳,获得10
1秒前
带善人完成签到,获得积分10
3秒前
听你发布了新的文献求助10
3秒前
4秒前
4秒前
gchen001完成签到,获得积分10
4秒前
脑洞疼应助z945采纳,获得10
4秒前
6秒前
Tian_lanlan发布了新的文献求助10
6秒前
7秒前
Ava应助xy采纳,获得10
8秒前
Coco完成签到,获得积分10
8秒前
肖ks完成签到,获得积分10
8秒前
852应助执着新蕾采纳,获得10
9秒前
careS完成签到,获得积分10
9秒前
leslie发布了新的文献求助10
10秒前
情怀应助豆子采纳,获得10
11秒前
欣喜念桃发布了新的文献求助10
11秒前
微笑访枫应助灰灰采纳,获得10
13秒前
wanci应助chongchong采纳,获得10
13秒前
SciGPT应助KevinDante采纳,获得30
13秒前
Owen应助chenli900108采纳,获得10
14秒前
14秒前
baozi发布了新的文献求助10
15秒前
goldNAN发布了新的文献求助10
16秒前
zommen发布了新的文献求助200
16秒前
lin发布了新的文献求助10
16秒前
量子星尘发布了新的文献求助10
16秒前
CodeCraft应助自然的书易采纳,获得10
17秒前
李爱国应助科研通管家采纳,获得10
17秒前
17秒前
arabidopsis应助科研通管家采纳,获得10
17秒前
8R60d8应助科研通管家采纳,获得30
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971277
求助须知:如何正确求助?哪些是违规求助? 3516009
关于积分的说明 11180382
捐赠科研通 3251075
什么是DOI,文献DOI怎么找? 1795664
邀请新用户注册赠送积分活动 875988
科研通“疑难数据库(出版商)”最低求助积分说明 805209